Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma.
Prapassorn ThirasastrHeather LinBehrang AminiWei-Lien WangJeffrey M CloutierElise F Nassif HaddadEmily Z KeungChristina L RolandBarry W FeigDejka AraujoRobert S BenjaminAnthony P ConleyJohn A LivingstonJoseph LudwigShreyaskumar R PatelRavin RatanVinod RaviMaria Alejandra ZarzourXiao ZhouNeeta SomaiahPublished in: Cancer medicine (2022)
Gemcitabine-docetaxel is an efficacious second-line treatment for DDLPS. Though cross study comparisons are not advisable, response to gemcitabine-docetaxel compares favorably to current standard options trabectedin and eribulin. This combination is a valid comparator arm for future second-line trials in DDLPS.